A Phase 3 interventional study of PRP Protocol A and PRP Protocol B in Osteoarthritis, Knee, sponsored by Instituto Nacional de Traumatologia e Ortopedia. Not yet recruiting at 1 site in Brazil. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-05-31.
Sponsored by Instituto Nacional de Traumatologia e Ortopedia · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Osteoarthritis, Knee with a site in Brazil — 12 open to participants now, 12 under way, 2 of them phase 3. Osteoarthritis, Knee · Brazil.
Among the 79 studies in Osteoarthritis, Knee with a site in Brazil, this one is the 29th largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 64th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →12 of the 79 studies in Osteoarthritis, Knee with a site in Brazil are open now. Recruiting first, the newest first:
University of Nove de Julho · Sites in Brazil
Ages 40–75
University of Nove de Julho · Sites in Brazil
Ages 40–80
University of Nove de Julho · Sites in Brazil
Ages 40–75
University of Nove de Julho · Sites in Brazil
Ages 40–80
University of Nove de Julho · Sites in Brazil
Ages 40–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 10 · Phase 4 9
First in 2005; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 66 across the 77 interventional studies, 38 across the 2 observational. Of the 49 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 79 have an industry lead sponsor. The 10 most frequent:
Instituto Nacional de Traumatologia e Ortopedia is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Instituto Nacional de Traumatologia e Ortopedia has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteoarthritis, Knee with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06187038University of Nove de JulhoEffects of Including a Chronic Pain Neuroscience Education Program for Individuals With Knee OA | 2026-11-30 |
| NCT06905860Federal University of São PauloIntra-articular Infiltration of Platelet-Rich Fibrin vs Corticosteroid in Mild to Moderate Knee Osteoarthritis | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies in Osteoarthritis, Knee with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Knee osteoarthritis (KOA) is a disease characterized by cartilage degeneration, synovium inflammation, bone remodeling, osteophyte formation, inflammations and loss of articular function. Interest on biological therapies has increased due to the recent update on KOA and its natural history. Viscosupplementation with hyaluronic acid aims to restore rheological properties of synovial fluid. Platelet rich plasma (PRP) is an autologous blood product which contains an elevated platelet concentration above the one found in blood. The goal of this study is to compare the clinical results of intra articular infiltration of hyaluronic and platelet rich plasma in the treatment of KOA, and to establish a protocol for PRP obtaining and prepare. Patients form the OA treating program will be selected and randomized into three groups (treatment with hyaluronic acid or onte of the two PRP protocols, PRP A and PRP B). Evaluation will include: subjective functional evaluation, clinical evaluation, radiological evaluation and radiological evaluation, which will be performed before treatment and 3 weeks, 3 months, 6 months and 1 year after treatment. Evaluation of PRP composition will be performed using ELISA/LUMINEX.
Key words: Knee, osteoarthritis, platelet rich plasma, viscosupplementation.
GROUP PRP Protocol A: Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP A), once a week, for three consecutive weeks; GROUP PRP Protocol B: Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP B), once a week, for three consecutive weeks; GROUP Hyaluronic acid: Composed of 30 patients who will receive an intra-articular injection of 2 mL of intra-articular hyaluronic acid (AHI), once a week, for three consecutive weeks.
PRP A will be prepared according to the following technique published previously elsewhere:
he preparation of PRP B will be carried out according to the following technique published previously elsewhere::
a) Collection of 50 mL of peripheral blood from the antecubital vein, in sterile vacuum collection tubes of 5 mL with 10% sodium citrate; b) Centrifuge the whole blood for 15 minutes at 1500 rpm, at room temperature, separating the material into two different layers (red blood cells, in the lower layer, and plasma, in the upper layer), in a 6.5 cm radius centrifuge; e) Separate and centrifuge the plasma for 7 minutes at 3500 rpm, creating two new layers (upper, which will be removed, lower, containing the platelets); Care must be taken to carefully aspirate the plasma from the closed tube using a syringe and needle and transfer it to a new collection tube, carefully injecting it through the cap; f) Prepare the material for infiltration in the knee; after preparation, it is estimated that 5 mL of PRP will be obtained, with half of the volume used for injection and the other half for analysis of the composition.
All infiltrations will be performed in the outpatient procedure room using aseptic technique. The technique for application will follow the steps below:
Finalize the procedure with a simple dressing.
The clinical evaluation will consist of the following steps:
Clinical assessment, consisting of (1) registration of demographic data (age, gender, weight, height, severity of osteoarthritis), (2) range of motion measurement, (3) assessment of the axis of the lower limbs (before infiltration , on the day of the third infiltration, three months, six months and one year after the infiltration; according to the knee cernter follow-up protocol); Radiographic evaluation with panoramic, anteroposterior and profile radiographs of the knees with load, aiming to detect alterations in the axis and joint space (before infiltration, 6 months and 1 year after infiltration, according to the knee center follow-up protocol).
Patients will be evaluated by an observer independent of the one who applied the selected treatment.
Peripheral blood samples from groups A and B will be processed to obtain PRP, with part of this product used in the application and part used to analyze the composition of the generated product.
Soon after preparation, a part of the product will be evaluated for hematological composition: total cell count, leukocytes and platelets, and mean platelet volume. The rest of the PRP will be stored, in aliquots of about 200ul, at the Cellular Technology Center, where it will remain frozen in a freezer at -80°C until the proteomic analysis (specified below) and the quantification of the factors and cytokines, through enzime linked immunoabsorbant assay and Luminex Kits: interleukin-1β, interleukin-6, interleukin-8, tumor necrosis factor-α, interferon-γ, interleukin-2, interleukin-2R, interleukin-7, interleukin-15, interleukin-17, interleukin-12p40 (pro-inflammatory cytokines); interleukin-1RA, interleukin-4, interleukin-5, interleukin-10, interleukin-13, interferon-α (anti-inflammatory cytokines); eotaxin, Interferon-gamma inducible Protein 10kDa, Membrane cofactor protein-1, interferon-γ-induced monokine, Macrophage inflammatory protein-1α, Macrophage inflammatory protein-1β (chemokines); endothelium growth factor, b-fibroblast growth factor, G-colony stimulating factor, vascular endotelium growth factor, transforming growth factor-β1, transforming growth factor-β2, transforming growth factor-β3, platelet derived growth factor-AB, platelet derived growth factor-BB, insulin growth factor-1 (growth factors).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Will be included in the study:
Exclusion Criteria:
Will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP A), once a week, for three consecutive weeks
Biological: PRP Protocol A
Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP B), once a week, for three consecutive weeks
Biological: PRP Protocol B
Composed of 30 patients who will receive an intra-articular injection of 2 mL of intra-articular hyaluronic acid (AHI), once a week, for three consecutive weeks.
Device: Hyaluronic acid
Platelet rich plasma protocol A
Platelet rich plasma protocol B
Hyaluronic acid
Evolution of Western Ontario and McMaster Universities Arthritis Index over time
Subjective pain and function score changes
Time frame: before infiltration, two weeks after first infiltration, three months, six months and one year after last infiltration
Evolution of Knee society score over time
Subjective function score changes
Time frame: before infiltration, two weeks after first infiltration, three months, six months and one year after last infiltration
Evolution of Visual analog pain scale over time
Subjective pain scale changes
Time frame: before infiltration, two weeks after first infiltration, three months, six months and one year after last infiltration
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2024; primary completion for Aug 2025, 12 months later.
Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 12 months is below that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Traumatologia e Ortopedia